https://doi.org/10.4081/reumatismo.2023.1623
Response to: myositis after SARS-CoV-2 vaccination occurs more frequently than assumed and is probably causally related
Published: 18 September 2023
Abstract Views: 803
PDF: 259
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
We thank Finsterer et al. for the attention paid to our publication; we recognize the validity of the points mentioned in their letter to the editor and will try to answer the observations made.
Finsterer J, MohanaSundaram AS, Scorza F. Myositis after SARS-CoV-2 vaccination occurs more frequently than assumed and is probably causally related. Reumatismo 2023, 75:(3). doi: 10.4081/reumatismo.2023.1601.
DOI: https://doi.org/10.4081/reumatismo.2023.1601
Al-Rasbi S, Al-Maqbali JS, Al-Farsi R, Al Shukaili MA, Al-Riyami MH, Al Falahi Z, et al. Myocarditis, pulmonary hemorrhage, and extensive myositis with rhabdomyolysis 12 days after first dose of Pfizer-Biontech BNT162b2 mRNA covid-19 vaccine: a case report. Am J Case Rep 2022; 23: e934399.
DOI: https://doi.org/10.12659/AJCR.934399
Rodrigues de Carvalho M, Sá de Deus Rocha MM, Alves Bezerra V, de Pontes ME, Del Negro MC, Antunes JS, et al. Anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase immune-mediated necrotizing myopathy following mRNA SARS-CoV-2 vaccination. Case Rep Neurol Med 2023; 2023: 7061783
DOI: https://doi.org/10.1155/2023/7061783
Syrmou V, Liaskos C, Ntavari N, Mitsimponas K, Simopoulou T, Alexiou I, et al. Covid-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report. Immunol Res 2023; 16: 1-10.
DOI: https://doi.org/10.1007/s12026-023-09368-2
Chang CH, Gupta R, Setyono D, Cuevas-Ocampo AK, Khoshnoodi MA. Refractory seronegative immune-mediated necrotizing myopathy after receiving mRNA-1273 SARS-CoV-2 vaccine: a case report. J Clin Neuromuscul Dis 2023; 24: 168-9.
DOI: https://doi.org/10.1097/CND.0000000000000431
Camargo Coronel A, Jiménez Balderas FJ, Quiñones Moya H, Hernández Zavala MR, Mandinabeitia Rodríguez P, Ramiro Hernández J, et al. Dermatomyositis post vaccine against SARS-COV2. BMC Rheumatol 2022; 6: 20.
DOI: https://doi.org/10.1186/s41927-022-00250-6
How to Cite
Quiñones-Moya, H. ., Camargo-Coronel, A. ., & Hernández-Zavala, M. (2023). Response to: myositis after SARS-CoV-2 vaccination occurs more frequently than assumed and is probably causally related. Reumatismo, 75(3). https://doi.org/10.4081/reumatismo.2023.1623
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- T. Ulas, H. Buyukhatipoglu, C. Bes, M.S. Dal, I. Hacıbekiroglu, H.G. Apucu, F. Borlu, Familial Mediterranean fever without cardinal symptoms and role of genetic screening , Reumatismo: Vol. 64 No. 3 (2012)
- A. Notarnicola, G. Lapadula, D. Natuzzi, F. Iannone, Possible interplay between interleukin-15 and interleukin-17 into the pathogenesis of idiopathic inflammatory myopathies , Reumatismo: Vol. 66 No. 3 (2014)
- L. Iaccarino, A. Ghirardello, M. Zen, D. Villalta, A. Tincani, L. Punzi, A. Doria, Polarization of TH2 response is decreased during pregnancy in systemic lupus erythematosus , Reumatismo: Vol. 64 No. 5 (2012)
- S. Barsotti, E. Cioffi, A. Tripoli, A. Tavoni, A. d’Ascanio, M. Mosca, R. Neri, The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature , Reumatismo: Vol. 70 No. 2 (2018)
- J. Finsterer, A.S. MohanaSundaram, F. Scorza, Myositis after SARS-CoV-2 vaccination occurs more frequently than assumed and is probably causally related , Reumatismo: Vol. 75 No. 3 (2023)
- R. Talotta, A. Berzi, F. Atzeni, D. Dell'Acqua, P. Sarzi Puttini, D. Trabattoni, Evaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients and correlation with anti-tumor necrosis factor therapy: results from an in vitro pivotal study , Reumatismo: Vol. 68 No. 2 (2016)
- C. Botsios, P. Sfriso, A. Furlan, P. Ostuni, M. Biscaro, U. Fiocco, S. Todesco, L. Punzi, Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis , Reumatismo: Vol. 59 No. 1 (2007)
- I. Bertoldi, B. Frediani, Osteoarthritis and osteoporosis: correlations between two clinical entities , Reumatismo: Vol. 65 No. 2 (2013)
- D. Mohamadzadeh, S. Assar, M. Pournazari, P. Soufivand, S. Danaei, Disseminated cutaneous herpes simplex infection after COVID-19 vaccination in a rheumatoid arthritis patient: a case report and review , Reumatismo: Vol. 74 No. 2 (2022)
- L. Bazzichi, D. Biasi, E. Tinazzi, M. Muratore, R. Pellerito, R. Russo, M. Corsaro Santi, P. De Sandre, O. Epis, M. Granata, B. Kroegler, C. Meschini, F. Versace, C. Astolfi, Safety of rituximab in the routine treatment of rheumatoid arthritis in Italy in patients refractory to anti-TNFa drugs: results from the observational retrospective-prospective RUBINO study , Reumatismo: Vol. 66 No. 3 (2014)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
You may also start an advanced similarity search for this article.
